article thumbnail

Contract manufacturing issue holds up Regenxbio’s Duchenne gene therapy trial

BioPharma Reporter

Regenxbio says it is to delay dosing of patients in its DMD gene therapy clinical trial following a quality issue at an unnamed third-party contract manufacturer.

article thumbnail

FDA Rejects Lilly’s Eczema Treatment Over Third-Party Manufacturing Issues

BioSpace

Eli Lilly’s Biologic License Application for its monoclonal antibody lebrikizumab was denied by the regulator after issues were found at a third-party contract manufacturing organization.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Torbay Pharma: 'We are all about making sterile supply simple'

BioPharma Reporter

Torbay Pharmaceuticals is a sterile injectable contract manufacturer and licence holder based in Devon, UK. We spoke with CEO Emma Rooth about the company's heritage and how it is striving to support the U.S.

article thumbnail

Lipidor signs cooperation agreement with contract manufacturer to offer licensees the opportunity for GMP production

The Pharma Data

Lipidor has already cooperated with the contract manufacturer Aurena Laboratories regarding hand and skin disinfection sprays and veterinary care products. This disclosure contains information that Lipidor is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014).

article thumbnail

Long lead times: Demand currently outstrips supply for contract manufacturing

BioPharma Reporter

As capital project delivery ramps back up to pre-pandemic levels over the coming months and years, the smaller biopharma players are looking outside their own resources for strategic manufacturing and research support, confirms a new market outlook from CRB.

article thumbnail

Covid-19 Omicron boosters will reinvigorate injectables manufacturing

Pharmaceutical Technology

Pfizer (New York, New York) and Moderna’s (Cambridge, Massachusetts) Omicron-specific Covid-19 vaccines are in late-stage development, have demonstrated good efficacy against the variant and will likely be available to the public later this year to provide an additional booster and increase demand for injectable manufacturing.

article thumbnail

CMO Moves: Regulatory catalysts for drug manufacturing-December

Pharmaceutical Technology

In this last 2022 edition of the series, which started in June , Pharmaceutical Technology is tracking major trial announcements and decisions by regulators and reimbursement agencies that have occurred since mid-October, as well as their potential impact on manufacturing plans.